Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

November 30, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide acetate 22.5 mg depot, GP-Pharm SA

Administered by im injection, twice during the study, three months apart

Trial Locations (25)

10016

Manhattan Medical Research, New York

10304

Staten Island Urological Research, PC, Staten Island

11215

Brooklyn Urology Research Group, Brooklyn

12208

The Urological Institute of Northeastern New York, Albany

12601

The Premier Medical Group of the Hudson Valley, PC, Poughkeepsie

19004

Urologic Consultants of SE PA, Bala-Cynwyd

19010

Urology Health Specialists, LLC, Bryn Mawr

20770

Mid Atlantic Clinical Research, Greenbelt

23462

Urology of Virginia, Virginia Beach

27103

PMG Research of Winston Salem, Winston-Salem

28401

PMG Research of Wilmington, Wilmington

29572

Carolina Urologic Research Center, Myrtle Beach

29650

Greenville Health System, Greer

32114

Atlantic Urological Associates, Daytona Beach

32803

Winter Park Urology Associates, PA, Orlando

34237

Coastal Medical Center, Sarasota

34474

Urology Health Team, Ocala

37209

Urology Associates, PC, Nashville

47130

First Urology, Jeffersonville

78229

Urology San Antonio Research, PA, San Antonio

83642

Idaho Urologic Institute, Meridian

83814

North Idaho Urology, Coeur d'Alene

92123

Genesis Research, San Diego

98166

Seattle Urology Research Center, Burien

08648

Premier Urology Associates, LLC, Lawrenceville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GP-Pharm

INDUSTRY